People

David C. Klonoff, M.D. is an endocrinologist specializing in diabetes technology. He is a Clinical Professor of Medicine at UCSF and the Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Health Services in San Mateo, California. Dr. Klonoff received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. He has been cited as being in the top 1% of endocrinologists nationally by Castle Connolly Medical Ltd. and as best endocrinologist in San Mateo County by Bay Area Consumer Checkbook. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as one of the 1000 top bioengineers in the world, as well as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology. He has authored over 200 publications. Dr. Klonoff founded the Diabetes Technology Meeting, the US and European Clinical Diabetes Technology Meetings, the Tissue Response to Implanted Medical Devices Meeting, and the International Hospital Diabetes Meeting. He was the lead investigator for the first randomized controlled multicenter trial of an outpatient closed loop control product, and published the results in the New England Journal of Medicine. Dr. Klonoff chaired the scientific advisory board for the first FDA-cleared insulin patch pump and participated in developing the first FDA-cleared dedicated diabetes telemedicine system, the two FDA-approved inhaled insulins, and the first three FDA-approved incretin drugs for diabetes. He is currently an advisor to Google for their smart contact lens project. Dr. Klonoff has chaired or served on grant review panels for NIH, CDC, NASA, NSF, US Army, ADA, JDRF, and U of Michigan. Dr. Klonoff is a graduate of UC Berkeley, where he was elected to Phi Beta Kappa in his junior year, and UCSF Medical School, where he was elected to Alpha Omega Alpha in his junior year. His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals. He was a member of the NIH Diabetes Interagency Coordinating Committee, whose ten-year research plan was released in 2011. Dr. Klonoff chaired the Endocrine Society Task Force on CGM Clinical Guidelines, the CLSI Subcommittee on CGM Metrics (POCT5), and the Diabetes Technology Society/FDA/ADA/Endocrine Society/AAMI Error Grid Panel. Dr. Klonoff currently chairs the Surveillance of FDA-Cleared Blood Glucose Monitors Program to determine the performance of cleared monitors. He is a member of the NSBRI Board of Scientific Counselors and the NASA Exploration Medical Capabilities Standing Review Panel.

Director, Diabetes Technology and Clinical Immunology Programs. 

Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) from the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH).

Select Experience            

Scientific Director, Diabetogen Biosciences, Inc., London, Ontario, Canada, 2000-2005

Senior Research Scientist, The Robarts Research Institute, Autoimmunity/ Diabetes Group, University of Western Ontario, 1998-2000

Postdoctoral Fellowship, The Robarts Research Institute, Autoimmunity/Diabetes Group, University of Western Ontario, 1994-1997

Research Fellowship, Endocrinology Research Laboratory, The Wellesley Hospital, Department of Medicine, University of Toronto, 1991-1994

Internal Medicine Specialty and Endocrinology Fellowship, University Hospital, Central University of Venezuela, 1985-1991                   

Current Responsibilities and Activities

Dr. Arreaza responsibilities include directing the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) program—which supports small business innovative research with potential for commercialization—in areas related to diabetes and endocrine diseases.  These areas include: drug discovery and technology development for diabetes and other endocrine diseases and their complications; new technologies for islet isolation, stem cell/regeneration, and transplantation; immune modulatory agents for the primary and secondary prevention of diabetes; inflammatory aspects of type 2 diabetes, insulin resistance, and obesity; and closed-loop systems/artificial pancreas development.

Dr. Arreaza is in charge of the academic program for technologies for the diagnosis and control of diabetes and is the program director for the Clinical Islet Transplantation (CIT) Consortium and the Clinical Islet Transplantation Registry (CITR) acting as executive secretary of the CIT- Consortium Data and Safety Monitoring Board (DSMB).  He also participates in the coordination of the new human islet research network (HIRN) program.  He has served as co-director of the Type 1 diabetes Rapid Access to Intervention Development (T1D-RAID) program and director of the preclinical testing in animal models of diabetes program, both cooperative efforts to facilitate translation of new and promising therapies. Dr. Arreaza also represents NIH in the Artificial Pancreas Interagency Working Group and participates in several NIDDK and NIH working groups and committees for the development and testing of novel therapies and technologies.

Dr. Arreaza is the author of 46 peer reviewed publications.  

Dr. Robert D. Burk is Professor and Vice Chair for Translational Medicine of Pediatrics; Professor of Microbiology & Immunology, of Obstetrics & Gynecology and Women’s Health, and of Epidemiology & Population Health. In addition, he is a Tenured Professor at the Albert Einstein College of Medicine (New York) since 2001. He is the recent recipient of the 2013 Saul R. Korey Award in Translational Science and Medicine and an Einstein Honorary Alumnus Award (2013).  He has extensive experience in molecular biology, epidemiology and assay development and validation. He has served as a consultant to the FDA for over 10 years.

He is an expert on the genomics and evolution of human papillomaviruses (HPV)—viruses best known as the primary cause of cervical cancer—Dr. Burk is chair of the Papillomavirus Working Group of the International Committee on Taxonomy of Viruses.  While his main research focus has been to understand the natural history of HPV infection of the cervix and the development of cervix cancer, as a geneticist, Dr. Burk is interested in how subtle changes in the HPV genome causes cancer. His investigations also include the association of HPV and head & neck cancer; the risk factors for prostate cancer among a population isolate; the molecular basis of von Hippel-Lindau mutations and development of renal cancer; and the genetic basis of excessive sweating (hyperhidrosis); more recently his lab is studying the role of the human microbiome on disease processes, particularly the gut microbiome and diabetes. One of his papers, which appeared in the New England Journal of Medicine, demonstrated that HPV has a short duration of infection in young women, and was fundamental in changing the medical management of young women with abnormal Pap smears; it has been cited over 2,500 times. He has published more than 350 peer-reviewed papers, was the past chair of the American Cancer Society Peer Review Committee on Molecular Genetics and Oncogenes and is currently an academic editor of PLOS ONE. He completed his medical degree at the George Washington University (GWU) School of Medicine, and worked in the laboratory of Dr. Marshall Nirenberg with Dr. John Minna at NIH, while in medical school and won both local and national awards for this research. Following an internship in General Surgery at UCSF, he switched fields to be more compatible with a scientific career. He completed residency training in Pediatrics also at UCSF and then completed a fellowship in Medical Genetics at the Johns Hopkins Medical Center. He is board certified in Pediatrics and Clinical Genetics.

Dr. Boris P. Kovatchev is Professor at the University of Virginia’s (UVA) School of Medicine, Adjunct Professor at the School of Engineering and Applied Science, and the founding Director of the UVA Center for Diabetes Technology. He received his Ph.D. degree in Mathematics from Sofia University “St. Kliment Ohridski,” Bulgaria in 1989. Kovatchev has a 20-year track record in mathematical modeling and computing, with primary focus on translational diabetes research. Currently, he is the Principal Investigator of several large projects dedicated to the development and clinical testing of closed-loop control and advisory systems for diabetes, including: (i) NIH Diabetes Impact Project DP3 DK 101055 at UVA and Stanford University; (ii) the JDRF Artificial Pancreas Project at UVA – a multi-center study that along with UVA involves the Universities of Padua (Italy), Montpellier (France), Stanford University, UC Santa Barbara, and the Sansum Diabetes Research Institute; (iii) NIH RO1 DK 085623 at UVA and Padua, and (iv) NIH RO1 DK 051562 focusing on the control of glucose variability. Kovatchev is also Co-Principal Investigator of a multi-center NIH Diabetes Impact Project (DP3 DK 094331) at UC Santa Barbara, UVA, and the Mayo Clinic and leads several industry-sponsored studies.  His projects resulted in in the [only] computer simulator of the human metabolic system accepted by FDA as a substitute to animal trials for the pre-clinical testing of insulin treatments, and in the first [worldwide] outpatient trials of portable artificial pancreas. Kovatchev is author of over 150 peer-reviewed publications and is a member of the editorial boards of IEEE Transactions on Biomedical Engineering and the Journal of Diabetes Science and Technology. He holds 38 U.S. and international patents and has numerous patent applications currently pending. In 2008 he received the U.S. Diabetes Technology Leadership Award; in 2011 he was named the UVA’s Edlich-Henderson Inventor of the Year, and in 2013 he was the recipient of JDRF’s Gerold and Kayla Grodsky Award presented for outstanding scientific contributions to diabetes research.

Expertise: Mathematical Modeling, Diabetes Technology, Continuous Glucose Monitoring, Closed-Loop Control and Artificial Pancreas.

Vice President, Artificial Pancreas

Aaron J. Kowalski, Ph.D., oversees JDRF-funded research aimed at accelerating the delivery and development of artificial pancreas systems.

Dr. Kowalski is an internationally recognized expert in the area of diabetes technologies and has been a leader of JDRF’s Artificial Pancreas Project, a multi-million dollar initiative that began in 2005 to accelerate the progress toward a closed-loop, automated insulin-delivery system. He has authored numerous articles in the field and was a co-author of the landmark study in The New England Journal of Medicine that revealed the effectiveness of continuous glucose monitors in T1D.

Dr. Kowalski has traveled widely across North America and abroad describing diabetes research progress, and is known for his ability to translate science into easily understandable concepts. Dr. Kowalski has been an invited speaker at many national and international conferences, including the ADA Annual Scientific Sessions, and was the keynote speaker at the 2009 Diabetes Technology Society Meeting. He has been a voice for diabetes research in the popular media, appearing on The Martha Stewart Show, dLife, Fox Business, NPR, and many other shows, and is often quoted in print media, including The New York Times, The Wall Street Journal, USA Today, and People magazine. He earned his doctorate in molecular genetics from Rutgers University and the University of Medicine and Dentistry of New Jersey.

In 1977 at the age of three, Dr. Kowalski’s brother Stephen was diagnosed with T1D and in 1984 at the age of 13 he too developed T1.

Courtney H. Lias, Ph.D. – Dr. Lias studied at the Johns Hopkins University School of Medicine where she received her Ph.D. in Biochemistry, Cellular, and Molecular Biology. After leaving Johns Hopkins in 2003, she joined the FDA’s Center for Devices and Radiological Health in the Office of In Vitro Diagnostics and Radiological Health. Currently, as the Director of the Division of Chemistry and Toxicology devices, she is involved in many diverse activities including premarket clearance/approval, manufacturer assistance, post market regulatory compliance actions, and the development of FDA Guidance for diagnostic devices. In addition, she has been an ongoing participant in multi-center FDA working groups focused on the developing fields of cardiovascular disease diagnosis, diabetes diagnosis/monitoring, clinical genetic testing, and biomarker development/validation.

Randie R. Little is a Research Professor in the Departments of Pathology & Anatomical Sciences and Child Health at the University of Missouri and is Director of the Diabetes Diagnostic Laboratory.  Dr. Little is the coordinator of the NGSP network and is a member of the NGSP Steering Committee and the IFCC Integrated Project on HbA1c.  She has published over 100 articles in the area of diabetes testing.  Her research interests include glycated hemoglobin (HbA1c) testing and standardization, evaluation and comparison of HbA1c methods, use of HbA1c for diabetes diagnosis and screening, use of glycated albumin and standardization of insulin and C-peptide measurement.  Recent publications include those on the effects of Hb variants on HbA1c measurements, Analytical Goals for HbA1c measurement and standardization of C-peptide measurements. 

is a Professor of Pathology, Microbiology, and Immunology, Medical Director of Clinical Chemistry, and Associate Medical Director for Clinical Operations at Vanderbilt University School of Medicine.  Dr. Nichols received his B.A. in General Biology/Premedicine from Revelle College, University of California at San Diego.  He went on to complete a Masters and Doctorate in Biochemistry from the University of Illinois, Urbana-Champaign.  Jim was a fellow in the Postdoctoral Training Program in Clinical Chemistry at the Mayo Clinic, Rochester, MN.  He is board certified in both Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.  Dr. Nichols spent several years as Associate Director of Clinical Chemistry, Director of Point-of-Care Testing, and an Associate Professor of Pathology at Johns Hopkins Medical Institutions.  Jim later served as Medical Director of Clinical Chemistry for Baystate Health in Springfield, MA and was a Professor of Pathology at Tufts University School of Medicine.  Dr. Nichols’ research interests span evidence-based medicine, information management, laboratory automation, point-of-care testing and toxicology.

Joan Lee Parkes, PhD has spent her professional life devoted to the field of diabetes research.  As a Postdoctoral Fellow she published a landmark paper in the Journal of Biological Chemistry on the regulation of glycogen metabolism in chick hepatocytes.  During her tenure as Assistant Professor at New York University School of Medicine she conducted research on the initiating events in atherosclerotic plaque development in persons with and without diabetes.

Joan then moved from academia to industry to work on products that could improve the quality of life for persons with diabetes. At Becton Dickinson (BD) she helped develop a clinical trials department that conducted studies on less painful lancing devices and lancets and on various types of insulin delivery devices including: insulin syringes, insulin pens, jet injectors, inhaled insulin, and transdermal patches.  During her stay at BD, she and colleagues conducted the research and published the highly referenced paper on the Parkes (or Consensus) Error Grid that is now part of the ISO 15197:2013 standards for blood glucose monitoring systems.  Subsequently as Director of Clinical Trials and Outcomes Research for Bayer Diabetes Care, Joan developed and led an excellent team devoted to clinical research on blood glucose monitoring systems including blood glucose meters with improved accuracy and usability as well as on continuous glucose monitoring systems.  Joan retired from Bayer in 2013.  She now is president of her own consulting company, Joan Lee Parkes Consulting, Inc. 

Throughout her career, Joan has published extensively on her research. 

 Joan has dedicated herself to the protection of human subjects in clinical trials and was founder and Chair of the Hudson Valley Institutional Review Board.

More recently, Joan has renewed her work with the Diabetes Technology Society (DTS) as a member of the Steering Committee for the recently published Surveillance Error Grid.  She currently is a member of DTS’s Blood Glucose Meter Post Market Surveillance Steering Committee.

Matt Petersen has been with the American Diabetes Association since 1993, first as managing editor of the Association's professional publications, and then as director of the Association's Research Program. Since 2001 he has directed the Association's Medical Information and Professional Engagement Department, which oversees the Association's messages about diabetes (diabetes treatment and management information, statistics, etc.) for the general public.  The department is also charged with improving and expanding the ways in which the Association provides services to its professional members and other health care professionals.

Mr. Petersen has broad responsibility for ensuring consistent messages about diabetes and diabetes issues throughout the organization. He also manages several education/information initiatives for consumers and healthcare professionals, and is responsible for the Association’s management and dissemination of information about statistical aspects of diabetes. He oversees the development of the Economic Costs of Diabetes Study as well as other statistical resources, including the ADA’s contribution to the National Diabetes Fact Sheet produced by the CDC.

Mr. Petersen leads the Association’s Health Information Technology Team and the Professional Engagement Team.  He developed and his department maintains the Association’s professional website, DiabetesPro, and he oversees the Association’s involvement with new technologies to deliver information and education content to consumers and health professionals.

Kelly Rawlings is the managing director, consumer publications, for the American Diabetes Association. Her primary responsibilities include directing editorial content for Diabetes Forecast magazine and website. She serves as the public member of the Board of Directors of the National Certification Board for Diabetes Educators and as a cochair of the Taking Control of Your Diabetes conference in Des Moines. Kelly, who has lived with diabetes since 1973, is an active member of the diabetes online community; find her on Twitter at https://Twitter.com/KellyRawlings. Kelly has a bachelor’s of arts degree in magazine journalism from Drake University, Des Moines. Currently, she is a part-time student in the Master of Public Health program at Des Moines University, a school of osteopathic medicine.

David B. Sacks is a Senior Investigator and Chief of Clinical Chemistry at the National Institutes of Health, Clinical Professor of Pathology at George Washington University and Adjunct Professor of Medicine at Georgetown University. Dr. Sacks obtained his medical degree from the University of Cape Town, South Africa. Further training included residencies in both Internal Medicine at hospitals affiliated with Georgetown Medical School and in Clinical Pathology at Washington University School of Medicine. He spent 21 years at Harvard Medical School.

Dr. Sacks’s primary clinical focus is in diabetes mellitus, with an emphasis on the interface between the clinical laboratory and patient care. He chaired the CLSI committees for both the 2nd and 3rd editions of POCT Blood Glucose Testing (C30-A and POCT12) and served as a liaison to the ISO/TC 212 Working Group. Currently he is Chair of the National Glycohemoglobin Standardization Program (NGSP) steering committee.  In addition, he serves on several other national and international committees. Dr. Sacks has authored over 175 research publications in peer-reviewed journals.  He is an Associate Editor of Clinical Chemistry and is a member of a number of other editorial boards. He was elected a Fellow of the Royal College of Pathologists in 1998.

Between 1985 and 2010, Dr. Eric J. Sampson served as the Director, Division of Laboratory Sciences (DLS) at the Centers for Disease Control and Prevention (CDC), Atlanta, GA. As Director, Dr. Sampson led a scientific staff of approximately 400 scientists (100+ PhDs, 6 MDs) and was involved in a number of precedent-setting epidemiologic studies and investigations in which laboratory data provided key information for resolving epidemics and/or formulating public health policy. 
 Major applied research and service laboratories within the Division focused on: tobacco and smoking addiction, clinical chemistry, environmental health, nutrition, newborn screening and genetics, and responding to chemical/radiologic terrorism. 


In 2010, the Director, CDC, asked Dr. Sampson to serve as a Senior Advisor at the Director’s Office, Food and Drug Administration (FDA), on science and policy issues between the agencies. His work involved a number of diverse areas including: food safety, nutrition, tobacco, and counterfeit drugs. Between 2011 and 2012, he also served as Acting Director of Science, Office of Regulatory Affairs, FDA.

Over the course of his career, Dr. Sampson has authored or coauthored more than 120 publications and has been the recipient of numerous awards including: the Young Investigator Award from the American Association of Clinical Chemistry; the Department of Health and Human Services Secretary’s Award for Distinguished Service; the Association of Public Health Laboratories President’s Award for service to the public health laboratory system; the Diabetes Technology Society Leadership Award; and the William C. Watson, Jr. Medal of Excellence Award, CDC’s highest award. Dr. Sampson has testified before Congressional committees and briefed congressional staffers on numerous occasions.

Since retiring in 2013, Dr. Sampson has been a consultant and serves as the Senior Science Advisor to the CDC Foundation.

Steven Scott is divisional vice president of research and development at Abbott Diabetes Care.

Steve joined MediSense in May 1986, as a project scientist. During the past 28 years he has held various management positions within the R&D and operations organizations, including manufacturing manager, technical operations manager, and U.K. research and development director, and was involved in several key product launches, including MediSense’s first blood glucose monitoring system, the ExacTech. 

Steve continued to lead the U.K. research and development organization following Abbott’s acquisition of MediSense in 1996, overseeing product and process design, including the launch of the MediSense Precision G test strip and the first MediSense ketone test strip.  The MediSense Products group was part of Abbott’s Diagnostics Division. In 2000, he was named U.S. research and development director. In this role, Mr. Scott continued to oversee U.K. test strip development as well as U.S. meter development.

Steve became divisional vice president in August 2002 and was responsible for the definition and implementation of MediSense’s R&D programs in the U.S. and the U.K., launching several new products.

After the acquisition of Therasense in 2004, Abbott Diabetes Care (ADC) was created as a separate division of Abbott.  Steve led the research and development of all of ADC’s in-vitro diagnostic projects and continued to launch new products including the no calibration FreeStyle Lite system and the subsequent FreeStyle strip upgrade (Omni) to include ZipWickTM technology.  Steve won Abbott’s Chairman’s Award in 2010 for his contribution to the launch of this significant upgrade. In 2010 Steve took over leading ADC’s sensor based research and development.

Steve earned a B.Sc. in chemistry from the University of Aberdeen in Scotland, and has completed executive development programs at Cornell University, NY and INSEAD, Fontainebleau, France.

Dr. Seley, is diabetes nurse practitioner and Program Manager of the Inpatient Glycemic Control Program in the Division of Endocrinology, Diabetes & Metabolism at NewYork-Presbyterian Hospital/Weill Cornell Medical College in New York City. She is an adjunct assistant professor at the Hunter-Bellevue School of Nursing and contributing editor and column coordinator of the American Journal of Nursing Diabetes Under Control column. She has published extensively in nursing and diabetes journals on the topics of diabetes management and education and is a co-author of the Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline (2012). She is a frequent presenter at diabetes and general conferences locally, nationally and internationally. Dr. Seley is a past-chair of the American Diabetes Association’s professional council on education. She is a current member of the American Association of Diabetes Educators (AADE) Board of Directors andserves on the editorial board of Diabetes Technology Society, Practical Diabetology and Diabetes Health.

Dr. Slingerland is a laboratory director responsible for Clinical Chemistry Department in the Isala

Klinieken, one of the largest hospitals in the Netherlands. The Clinical Chemistry Department employs 250 people. The laboratory serves the hospital as well as family doctors. Coagulation service and a transplantation laboratory are part of the laboratory. The laboratory supports e.g. the cardiology department that serves about 1.3 million people.

His span of control includes Point-of-Care Testing, Diabetes and Cardiology investigations, Special chemistry and Quality Assurance conducted through the Isala Clinics. Also Home-Use Testing is his responsibility.

As chair of the European Reference Laboratory he is responsible for the production of the world gold standard for HbA1c (primary reference material) and secondary reference material which is made available to all manufacturers in the world. The European Reference Laboratory makes also the HbA1c-materials for EQUAS-organizers to check the quality at the user-level.

Two primary reference methods are run in his lab (HbA1c and glucose) as well as 3 secondary

reference methods for HbA1c and 3 secondary reference methods for glucose. All home-use glucose meters including new strip batches on the Dutch market are yearly tested in the Isala Clinics.

The Isala Clinics has a long tradition in Point-of-Care Testing

Hubert W. Vesper, PhD is the Director of Clinical Standardization Programs and Chief of the Lipid Reference and Protein Biomarker Laboratories at the Center for Disease Control and Prevention (CDC). He is leading the CDC standardization programs on cholesterol, blood lipids, steroid hormones and vitamin D. As consultant and advisor, he assists national and international programs with monitoring and improving clinical laboratory testing such programs operated by the National Glycohemoglobin Standardization Program (NGSP), the National Bone Health Alliance, the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC), and the American Association of Clinical Chemists (AACC) Harmonization Imitative. Dr. Vesper is an advisor and consultant to organizations developing laboratory standards such as the Clinical Laboratory Standards Institute (CLSI) and the International Standards Organization (ISO). As co-founder of the Partnership for the Accurate Testing of Hormones (PATH) and the AACC Endocrinology Division, Dr. Vesper is leading efforts to improve patient testing through training and education of the clinical, public health and medical communities. Dr. Vesper directs research in the areas of cardiovascular diseases, diabetes, cancer and bone diseases. He is developing new analytical methods to measure biomarkers in humans and is applying these methods to investigate biomarker levels in the general population such as the National Health and Nutrition Examination Survey (NHANES) and other studies. Dr. Vesper authored and co-authored over 50 papers in peer reviewed journals and to several guidelines, standards and position papers.

Hubert W. Vesper, PhD is the Director of Clinical Standardization Programs and Chief of the Lipid Reference and Protein Biomarker Laboratories at the Center for Disease Control and Prevention (CDC). He is leading the CDC standardization programs on cholesterol, blood lipids, steroid hormones and vitamin D. As consultant and advisor, he assists national and international programs with monitoring and improving clinical laboratory testing such programs operated by the National Glycohemoglobin Standardization Program (NGSP), the National Bone Health Alliance, the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC), and the American Association of Clinical Chemists (AACC) Harmonization Imitative. Dr. Vesper is an advisor and consultant to organizations developing laboratory standards such as the Clinical Laboratory Standards Institute (CLSI) and the International Standards Organization (ISO). As co-founder of the Partnership for the Accurate Testing of Hormones (PATH) and the AACC Endocrinology Division, Dr. Vesper is leading efforts to improve patient testing through training and education of the clinical, public health and medical communities. Dr. Vesper directs research in the areas of cardiovascular diseases, diabetes, cancer and bone diseases. He is developing new analytical methods to measure biomarkers in humans and is applying these methods to investigate biomarker levels in the general population such as the National Health and Nutrition Examination Survey (NHANES) and other studies. Dr. Vesper authored and co-authored over 50 papers in peer reviewed journals and to several guidelines, standards and position papers.